# Clinical Trial on Pharmacokinetic and Tolerability of AP701

> **NCT04708795** · PHASE1 · COMPLETED · sponsor: **CannaXan GmbH** · enrollment: 15 (actual)

## Conditions studied

- Pharmacokinetic
- Tolerability
- Safety

## Interventions

- **DRUG:** AP701

## Key facts

- **NCT ID:** NCT04708795
- **Lead sponsor:** CannaXan GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-11
- **Primary completion:** 2021-03-07
- **Final completion:** 2021-03-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04708795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04708795, "Clinical Trial on Pharmacokinetic and Tolerability of AP701". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04708795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*